Troy– Author –
-
Austrian Cell Therapy Startup Innovecell Lists on Tokyo Stock Exchange Growth Market, Raises ¥11.7B for Global Aggregation Model Focused on Incontinence Therapy
Moomoo Japan Overview Innovecell, a cell therapy startup spun out from the Medical University of Innsbruck, specializing in autologous cell therapies for urinary incontinence, listed on the Tokyo Stock Exchange Growth Market in February ... -
FDA Unleashes Real-Time Clinical Trials: An AI-Driven Revolution for Faster Drug Development
ICON plc アイルランド Overview The U.S. FDA has launched its Real-time Clinical Trials (RTCT) initiative, a pivotal program designed to dramatically accelerate drug development. By enabling near real-time data sharing with regulators and... -
Real-World Data for Follicular Lymphoma CAR T-Cell Therapy Maintains Trial-Level Response Rates but Shows Shorter Progression-Free Survival
The Limbic Australia Overview A real-world analysis of commercial CAR T-cell therapies (axi-cel and tisa-cel) for relapsed/refractory follicular lymphoma (FL) demonstrated comparable response rates to those observed in clinical trials, d... -
PwC Report: Biopharma Ecosystem Fully Recovers with 16 M&A Deals Over $1B in Q1 2026, Driven by Next-Gen Modalities and GLP-1 Expansion
Fierce Pharma USA Overview A recent PwC report indicates the biopharma ecosystem has 'returned to full health,' with 16 M&A transactions exceeding $1 billion in Q1 2026. Deals primarily focused on 'differentiated science, GLP-1 expan... -
Portal Biotechnologies Raises $9M to Expand Cell Engineering Platform, Attracting Merck & Co. and AbbVie
FirstWord HealthTech USA Overview Portal Biotechnologies secured $9 million to advance its cell engineering platform, which has drawn partnerships with Merck & Co. and AbbVie. The platform leverages mechanoporation for efficient intr... -
Cellares Secures $327M in Series D Funding, Including ARK Invest, and Expands Major Manufacturing Agreements with Bristol Myers Squibb and Cabaletta Bio
AllSci USA Overview Cellares has extended its Series D financing to $327 million with a new $50 million investment, specifically aimed at scaling cell therapy manufacturing. As an Integrated Development and Manufacturing Organization (ID... -
Biotech M&A in 2026: Manufacturing Complexity and Cost Remain Key Constraints to Commercial Scalability
Financier Worldwide UK Overview Despite accelerating M&A activity in biotech and life sciences in 2026, experts indicate that the manufacturing complexity and high costs of cell and gene therapies continue to limit commercial scalabi... -
Pharmaceutical and Biotech M&A Surges in 2026, Driven by Pipeline Reinforcement and Expansion into Emerging Therapeutic Areas
DistilINFO Publications USA Overview The pharmaceutical and biotechnology sectors are experiencing a significant surge in M&A activity in 2026, as major drugmakers actively seek to fortify their pipelines and expand into novel therap... -
CCRM, OmniaBio, and Avectas Collaborate to Automate and Scale Cell Therapy Manufacturing
PR Newswire Canada Overview CCRM and its CDMO subsidiary OmniaBio Inc. have partnered with Avectas Limited to evaluate and integrate Avectas' automated, scalable cell therapy manufacturing platform. This collaboration aims to enhance con... -
Top Cell Therapy Startups Secure Significant Funding for Commercialization, Infrastructure, and Novel Modalities
New Market Pitch USA Overview Leading cell therapy startups are attracting substantial investment, indicating investor confidence in high-risk technical innovation. Companies like Orca (near-commercial assets), Cellares (manufacturing in...
